Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more
reimbursed by the French healthcare system, due to a controversy about its efficiency. French
health authorities currently preconize a non-rug approach based on cognitive remediation or
stimulation.
The aim of this study is to compare the efficiency of the 2 approaches (non-drug versus
donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.